ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,470
-340 (-2.65%)
Jul 18, 2025, 3:30 PM KST
-64.47%
Market Cap135.95B
Revenue (ttm)6.51B
Net Income (ttm)-16.95B
Shares Out10.90M
EPS (ttm)-1,774.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume48,492
Average Volume71,626
Open12,770
Previous Close12,810
Day's Range12,360 - 12,770
52-Week Range11,700 - 45,800
Betan/a
RSI48.75
Earnings Daten/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2024, ENCell's revenue was 7.21 billion, a decrease of -31.51% compared to the previous year's 10.53 billion. Losses were -15.21 billion, 201.0% more than in 2023.

Financial Statements

News

There is no news available yet.